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ABSTRACT
INTRODUCTION In 2018, the European Network for Smoking Cessation 
and Prevention (ENSP) released an update to its Tobacco Treatment 
Guidelines for healthcare professionals, which was the scientific 
base for the development of an accredited eLearning curriculum to 
train healthcare professionals, available in 14 languages. The aim 
of this study was to evaluate the effectiveness of ENSP eLearning 
curriculum in increasing healthcare professionals’ knowledge, 
attitudes, self-efficacy (perceived behavioral control) and intentions 
in delivering tobacco treatment interventions in their daily clinical 
routines. 
METHODS We conducted a quasi-experimental pre-post design study 
with 444 healthcare professionals, invited by 20 collaborating 
institutions from 15 countries (Albania, Armenia, Belgium, Italy, 
France, Georgia, Greece, Kosovo, Romania, North Macedonia, 
Russia, Serbia, Slovenia, Spain, Ukraine), which completed the 
eLearning course between December 2018 and July 2019.
RESULTS Healthcare professionals’ self-reported knowledge improved 
after the completion of each module of the eLearning program. 
Increases in healthcare professionals’ self-efficacy in delivering 
tobacco treatment interventions (p<0.001) were also documented. 
Significant improvements were documented in intentions to address 
tobacco use as a priority, document tobacco use, offer support, 
provide brief counselling, give written material, discuss available 
medication, prescribe medication, schedule dedicated appointment 
to develop a quit plan, and be persistent in addressing tobacco use 
with the patients (all p<0.001). 
CONCLUSIONS An evidence-based digital intervention can be effective 
in improving knowledge, attitudes, self-efficacy and intentions on 
future delivery of tobacco-treatment interventions.
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INTRODUCTION
Tobacco use is the most significant threat to 
European Public Health and directly associated 
with morbidity and mortality1. More than a quarter 
(26%) of Europeans still smoke1. Smoking cessation 
is one of the main strategies suggested by the World 
Health Organization’s (WHO) MPOWER package 
against the tobacco epidemic, presenting the first 
comprehensive worldwide analysis of tobacco use and 
control efforts2. The WHO Framework Convention 
on Tobacco Control (WHO FCTC) Article 14 and 
its implementation guidelines call on its Parties to 
‘facilitate accessibility and affordability for treatment 
of tobacco dependence’2. Healthcare professionals 
have a key role to play in supporting tobacco treatment 
delivery, one of the targets of the WHO MPOWER 
package and FCTC3.
Training is an integral part of supporting tobacco 
treatment delivery and has been shown to increase 
the likelihood of healthcare professionals delivering 
evidence-based tobacco treatment. Despite this, 
only a fraction of European healthcare professionals 
have completed training as part of their formal 
undergraduate education or as part of continuing 
medical education4. Recent reviews show that there 
is a gap in the use of advanced computer-based 
medical education approaches on tobacco treatment 
training for healthcare professionals, and there is a 
need to support the training/education of healthcare 
professionals in behavioral change in Europe4. 
In 2018, the European Network for Smoking 
Cessation and Prevention (ENSP) released an update 
to its tobacco treatment guidelines for healthcare 
professionals5. The guidelines summarize the latest 
evidence and provide recommendations for healthcare 
professionals (www.elearning-ensp.eu). An eLearning 
curriculum was developed to train healthcare 
professionals in the guideline recommendations, 
available in 14 languages.
This study reports on the effectiveness of an 
accredited eLearning curriculum that aimed to 
increase healthcare professionals’ knowledge, and to 
change attitudes, self-efficacy (perceived behavioral 
control) and intentions in delivering tobacco-
treatment interventions in their daily clinical life.
 
METHODS
In the context of EPACTT-Plus, collaborating 
institutions from 15 countries (Albania, Armenia, 
Belgium, Italy, France, Georgia, Greece, Kosovo, 
Romania, North Macedonia, Russia, Serbia, Slovenia, 
Spain, Ukraine) worked to develop an accredited 
eLearning course on Tobacco-Treatment Delivery 
available at http://elearning-ensp.eu/. This five-
module eLearning training course was accredited by 
the European Accreditation Council for Continuing 
Medical Education (EACCME) for 2 CME credits. 
Ajzen’s Theory of Planned Behavior (TPB) was used to 
guide intervention design. The TPB incorporates both 
social influences and personal factors as predictors, 
specifying a limited number of psychological variables 
that can influence behavior such as attitude, subjective 
norms, perceived behavioral control (PBC), and 
intention6. 
eLearning curriculum
The curriculum includes five different training 
modules as well as case studies, quizzes, and 
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interactive content. The course was developed in 
Moodle, and is available at www.elearning-ensp.eu. 
At the end of each module, a knowledge assessment 
is completed by users. 
Module 1 
This module is entitled ‘Nicotine Addiction - Why 
people smoke?’ and discusses why it is so difficult 
for individuals to quit smoking. The physical and 
psychological aspects of tobacco use are reviewed, as 
well as the pathophysiology of nicotine addiction and 
the associated withdrawal symptoms and cravings that 
can make quitting challenging. In addition are discussed 
the connections between daily routines, triggers to 
smoke and mood in maintaining tobacco use.
Module 2 
This module is entitled ‘How to help your patients quit 
smoking’. The important role of health professionals 
in supporting cessation among patients who smoke 
as a clinical priority is reviewed as well as a brief 
overview of the 5As model for integrating tobacco 
dependence treatment into clinical settings. The 5As 
include: ‘Ask’ patients about smoking status; ‘Advice’ 
them to quit smoking; ‘Assess’ their readiness to quit 
smoking; ‘Assist’ them with making a quit attempt; 
and ‘Arrange’ a follow-up meeting.
Modules 3 and 4
The behavioral counselling content is divided into 
two parts, Modules 3 and 4. In Module 3, the role of 
behavioral counselling as a treatment for supporting 
tobacco users with quitting is discussed as well as 
evidence-based counselling strategies designed 
for individuals ready to quit smoking in order to 
increase their likelihood of successfully quitting. In 
Module 4, key behavioral strategies used to enhance 
motivation among patients who are not ready to 
quit smoking include motivational interviewing and 
smoking reduction approaches. These two modules 
also include examples of how to deliver behavioral-
change techniques as an active learning method.
Module 5 
This module provides training on pharmacological 
treatment as a fundamental component of treating 
tobacco use. In this module, first-line quit smoking 
medications are discussed including Nicotine 
Replacement Therapy, Bupropion, Varenicline and 
their appropriate use in clinical practice in order to 
maximize success with smoking cessation among 
patients. A brief overview of other quit-smoking 
medications that are emerging as promising therapies 
are also presented to learners. Several interactive case 
studies are embedded in this module as an active 
learning method.
Adaptation and translation of the material
In order to adapt and translate the eLearning content 
for each participating country, local champions were 
engaged. The training program was adapted and 
translated into 14 different languages (Albanian, 
Armenian, English, French, Georgian, Greek, Italian, 
Macedonian, Romanian, Russian, Serbian, Slovenian, 
Spanish, Ukrainian) and released in 2018.
Evaluation of the training curriculum
During the recruitment period, an email to relevant 
healthcare professionals was sent from collaborating 
institutes in each country, to invite them to take the 
courses. A cut-off of 30 participants per language was 
set as a limit for the evaluation, while the complete 
duration of the sessions was about two and a half 
hours of online training.
A pre-post assessment was embedded in the structure 
of the eLearning courses. During the pre-assessment, 
and following the provision of consent, participants 
reported their demographic characteristics, current 
practices in delivering tobacco treatment practices 
(5As delivery with 9 components), their normative 
beliefs (5 components), attitudes (6 components), self-
efficacy in delivering tobacco treatment interventions 
(5 components), perceived importance in providing 
these interventions (1 component), and intentions (9 
components). During the post-assessment, the same 
variables were assessed to document changes. In 
addition to the above, before and after each module, 
participants completed a knowledge assessment. A 
score of 80% or higher was required to pass the test. 
The tools used to evaluate the training curriculum have 
been previously tested in several studies conducted 
from members of our team7-11. 
Statistical analysis
Quantitative variables that followed normal 
distributions are presented as means and standard 
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deviations (SD). Quantitative variables that did not 
follow a normal distribution and ordinal variables 
are presented as median and interquartile range 
(non-parametric methods). Qualitative variables 
are expressed as frequencies and percentages. In 
the case of related samples (paired comparisons), 
paired t-test (when the variable was continuous 
and followed a normal distribution) and Wilcoxon 
signed-rank test (when the variable did not follow 
a normal distribution or was an ordinal variable) 
were used. In this case, results are presented as the 
median difference, 95 % confidence interval for the 
difference and IQR 25–75, while a z-test was used 
for the difference of the median between the pre-test 
ranks and the post-test ranks. Statistical significance 
was set at 0.05. All analyses were performed in IBM 
SPSS statistical software package version 23.0.
RESULTS
From December 2018 to July 2019, a total of 444 
healthcare professionals were enrolled and completed 
the course. Table 1 presents the characteristics of 
participating healthcare professionals and their 
practices. The majority of the participants were female 
(73.4%), under 30 years of age (43.6%), working in 
the public sector (73.9%) and urban settings (81.9%). 
Most of the participants (68.9%) had not participated 
in smoking cessation training in the past, while 32.2% 
reported being smokers (67.8%). 
Table 2 depicts the recorded changes in healthcare 
professionals’ self-reported knowledge before and 
after the completion of each module of the eLearning 
program. Statistically significant changes were 
documented for all knowledge questions, except one, 
of Module 1, Module 2, and behavioral counselling 
Modules 3 and 4 (p<0.001). A significant increase in 
participant’s knowledge regarding pharmacotherapy 
(Module 5) was also recorded. For example, there was 
an increase in knowledge regarding the safety of the 
NRT (45.7% vs 97.0%; p<0.001) and the most common 
side effect of Varenicline (68.5% vs 96.2%; p<0.001).
Table 3 presents the changes in healthcare 
professionals’ self-reported attitudes, normative beliefs, 
self-efficacy (perceived behavioral control), intentions 
of delivering tobacco treatment interventions as well 
as the importance of smoking cessation interventions, 
before and after the completion of the eLearning 
curriculum. Favorable changes were documented for 
attitudes in five out of six areas assessed. Normative 
beliefs of the participants also changed after the course 
with statistically significant results in four out of the 
five statements. A statistically significant increase in 
healthcare professionals’ self-efficacy to help their 
patients quit smoking was documented between the 
pre- and post-intervention assessment (z-score = 
-13.083; p<0.001). 
Table 1. Characteristics of healthcare professionals 
who participated in the ENSP eLearning for treating 
tobacco dependence
Variables n %
Gender
Male 118 26.6
Female 326 73.4
Age (years)
<30 193 43.5
30–39 85 19.1
40–49 93 20.9
50–59 48 10.8
60–69 24 5.4
≥70 1 0.2
Practice setting
Private 116 26.1
Public 328 73.9
Geographical location
Urban 363 81.9
Suburban 45 10.2
Rural 35 7.9
Employment status
Part-time 80 18.0
Full-time 364 82.0
Previous training in smoking cessation 
Yes 138 31.1
No 306 68.9
Health care provider smoking status
Smoker 33 7.4
Ex-smoker 110 24.8
Non-smoker 301 67.8
Practice supporting facilities for treating 
tobacco dependence
Process to screen and document smoking status 
of patients
242 56.5
Self-help materials for smokers 120 28.0
Consult forms to guide through quit smoking 
counselling interventions
66 15.4
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Continued
Table 2. Proportion of trainees who responded correctly to knowledge assessment at the pre- and post-
assessments 
Variables Pre
n (%)
Post
n (%) 95% Cl* p**
Knowledgea
Nicotine addiction Module 1
For most smokers, tobacco use is… 186 (42.3) 394 (89.5) 0.420–0.525 <0.001
Nicotine is as addictive as other drugs such as heroin or cocaine. 350 (79.5) 424 (96.4) 0.129–0.208 <0.001
Which of the following are common withdrawal symptoms experienced when someone 
quits smoking?
369 (83.9) 432 (98.2) 0.107–0.179 <0.001
How soon may someone begin to experience withdrawal symptoms when they go 
without a cigarette?
149 (33.9) 386 (87.7)  0.482–0.595 <0.001
Which of the following are not true about nicotine withdrawal symptoms? 192 (43.6) 373 (84.8)  0.356–0.466 <0.001
What proportion of smokers report night wakening or difficulty sleeping after they 
quit?
230 (52.3) 417 (94.8)  0.373–0.477 <0.001
The majority of patients who quit smoking experience irritability, restlessness, and 
depression?
332 (75.5) 420 (95.5) 0.157–0.243 <0.001
Which of the following are not true about people who are fast nicotine metabolizers? 311 (70.8) 419 (95.4) 0.198–0.294 <0.001
What are the most common reasons people return to smoking in the first few weeks 
after quitting?
336 (76.4) 428 (97.3) 0.166–0.252 <0.001
People who quit smoking will have more, less, or the same amount of stress? 185 (42.0) 399 (90.5)  0.434–0.537 <0.001
How to help patients quit Module 2
Tobacco treatment should be delivered with the same rigor and clinical importance as 
any other major chronic risk factor. 
418 (94.6) 436 (98.6) 0.019–0.062 <0.001
A clinician’s advice to quit is not very effective in motivating patients to quit. 327 (74.0) 425 (96.2)  0.176–0.268 <0.001
Advice to quit smoking should be… 348 (78.7) 429 (97.1)  0.143–0.223 <0.001
Offering patients your support with quitting has been shown to increase patient 
motivation to quit. 
409 (92.5) 439 (99.3) 0.042–0.094 <0.001
If a patient informs you they are not ready to quit, what should you do? 396 (89.6) 437 (98.9) 0.064–0.122 <0.001
Which of the following questions are important pieces of information gathered as part 
of the smoking history? (check all that are correct)
382 (86.4) 435 (98.4) 0.086–0.153 <0.001
Which of the following are important pieces of information to discuss with patients 
when developing a motivational intervention or personalized quit plan?
383 (86.8) 434 (98.4) 0.082–0.149 <0.001
Patients that have higher levels of nicotine dependence can be assessed by… 262 (59.3) 390 (88.2) 0.236–0.344 <0.001
For patients who report they are interested in quitting smoking, evidence has shown 
that the most effective evidence-based treatments are… 
324 (73.3) 418 (94.6) 0.170–0.255 <0.001
It is recommended that follow-up be scheduled 2–8 weeks, following the patient’s 
initial consultation, to review progress and response to therapy and make any 
adjustments to the plan.
371 (84.3) 432 (98.2) 0.102–0.176 <0.001
Which of the following are not true about follow-up support for individuals who are 
quitting smoking?
301 (68.3) 414 (93.9) 0.209–0.303 <0.001
Behavioral counseling Modules 3 and 4
The main goals of behavioral counselling are to… 349 (79.0) 419 (94.8) 0.117–0.199 <0.001
There is no evidence that counselling helps patients to quit smoking. 365 (82.6) 429 (97.1) 0.107–0.183 <0.001
Which of the following are true? 385 (87.3) 430 (97.5) 0.070–0.134 <0.001
How long does a craving typically last? 231 (52.3) 426 (96.4) 0.392–0.490 <0.001
The 4Ds strategies are the recommended approach for dealing with cravings to smoke 
and include.
319 (73.0) 427 (97.7) -1.397–0.985  0.734
Recent quitters are still vulnerable to relapse, especially in the first three to six months 
after quitting.
412 (93.2) 428 (96.8) 0.007–0.066  0.016
Motivational interviewing is… 233 (52.8) 394 (89.3) 0.311–0.419 <0.001
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Table 3. Self-reported attitudes, normative beliefs, perceived behavioral control and intention changes of the 
healthcare professionals that participated in the ENSP eLearning for treating tobacco dependence
Variables Pre
 Median 
(IQR)
Pre 
IQR***
25–75
Post 
Median 
(IQR)
Post 
IQR***
25–75
z-score* p
Attitudesa
Counseling by a clinician helps motivate smokers to quit. 5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -7.370 <0.001
For many tobacco users smoking is an addiction. 5.0 (1.0) 4.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -2.820  0.005
First line pharmacotherapies for smoking cessation work well in 
helping patients quit.
3.0 (1.0) 3.0 – 4.0 5.0 (1.0) 4.0 – 5.0 -13.243 <0.001
First line pharmacotherapies for smoking cessation have side 
effects that outweigh their benefits.
2.0 (2.0) 1.0 – 3.0 1.0 (2.0) 1.0 – 3.0 -4.265** <0.001
Tobacco use is killing too many people. 5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -1.390  0.164
It is my usual practice to assist my patients to quit smoking. 4.0 (2.0) 4.0 – 5.0 4.0 (1.0) 4.0 – 5.0 -5.346 <0.001
Table 2. Continued
Variables Pre
n (%)
Post
n (%) 95% Cl* p**
The goal of motivational interviewing is not necessarily to get the patients to change 
but rather to get the patient talking and thinking about changing their smoking 
behavior.
353 (80.0) 436 (98.6) 0.150–0.226 <0.001
Motivational interviewing techniques clinicians should use, include… 358 (81.0) 431 (97.5) 0.127–0.203 <0.001
Developing discrepancy between a patient’s current behavior and expressed priorities, 
values and goals is a strategy used as part of motivational interviewing. This can be 
done by…
180 (40.7) 344 (77.8) 0.117–0.199 <0.001
Pharmacotherapy Module 5
Are nicotine replacement therapies contraindicated for people with cardiovascular 
disease?
318 (72.6) 426 (97.3) 0.203–0.290 <0.001
Is it safe to continue to smoke while using nicotine replacement therapy? 201 (45.7) 427 (97.0) 0.464–0.563 <0.001
Nicotine replacement therapy should only be used for a maximum of 12 weeks. 244 (55.5) 399 (90.7) 0.299–0.406 <0.001
You may use any form of nicotine replacement therapy alone but they should not be 
used in combination.
248 (56.5) 431 (98.2) 0.369–0.465 <0.001
A patient smokes 1 pack of cigarettes per day and smokes within 5 minutes of waking 
in the morning. What dose of NRT should he be started on?
206 (46.8) 342 (77.7) 0.255–0.363 <0.001
A patient is using NRT but reports severe cravings and is concerned he/she may return 
to smoking. What do you recommend?
244 (55.5) 402 (91.4) 0.307–0.411 <0.001
A woman using Bupropion reports a variety of side effects since beginning the 
medication. What do you recommend to address this issue?
242 (55.0) 396 (90.0) 0.298–0.402 <0.001
Bupropion is contraindicated among… (Click all that apply) 353 (80.2) 427 (97.0) 0.128–0.208 <0.001
What is the most common side effects of Varenicline? 300 (68.5) 425 (96.2) 0.232–0.325 <0.001
Which of the following strategies can be used for patients who report experiencing 
nausea while using Varenicline?
229 (52.0) 378 (85.9) 0.280–0.397 <0.001
Patients using Varenicline should be advised to quit smoking how many weeks after 
using the treatment?
22 (50.9) 339 (77.0) 0.206–0.317 <0.001
For patients using Varenicline who experience vivid dreams it can be recommended that 
they…
333 (75.9) 428 (97.5) 0.175–0.258 <0.001
It is safe to use Varenicline for 6-month period or longer? 247 (56.3) 371 (84.5) 0.225–0.340 <0.001
Which are the most effective medications in terms of increasing success rates 355 (80.7) 433 (98.4) 0.139–0.216 <0.001
a Multiple choice questions. *95% confidence interval of difference between pre- and post-assessments. **McNemar-Bowker test.
Continued
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An increase was also documented in the intention 
to address tobacco use as a priority (z-score = -4.414; 
p<0.001), document tobacco use (z-score = -6.703; 
p<0.001), offer support (z-score = -7.022; p<0.001), 
provide brief counseling (z-score = -5.586; p<0.001), 
give written material (z-score = -4.719; p<0.001), 
discuss available medication (z-score = -9.726; 
p<0.001), prescribe medication for smoking cessation 
(z-score = -8.345; p<0.001), schedule dedicated 
appointment to develop a quit plan (z-score = -7.327; 
p<0.001) and be persistent on addressing tobacco use 
with the patients even if they are not effective the first 
time (z-score = -5.911; p<0.001). 
DISCUSSION
Our study evaluated the effectiveness of an accredited 
eLearning curriculum in increasing key constructs 
known to be related to tobacco treatment delivery. 
Results indicated that the eLearning program 
improved participants’ knowledge, attitudes, beliefs, 
self-efficacy (perceived behavioral control) and 
intentions associated with the delivery of evidence-
Table 3. Continued
Variables Pre
 Median 
(IQR)
Pre 
IQR***
25–75
Post 
Median 
(IQR)
Post 
IQR***
25–75
z-score* p
Normative beliefsa
Smoking cessation is an important part of my role as a healthcare 
professional.
5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -5.316 <0.001
Smoking is a personal decision which does not concern the 
healthcare professional.
1.0 (2.0) 1.0 – 3.0 1.0 (2.0) 1.0 – 3.0 -0.360  0.719
Healthcare professionals should advise patients to quit smoking 
even if it is not the reason for the visit.
5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -2.562 0.010
Healthcare professionals should make appointments specifically to 
help patients quit.
5.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -5.096 <0.001
A patient’s will power alone is what will determine their success 
with quitting.
4.0 (1.0) 2.0 – 4.0 3.0 (2.0) 2.0 – 4.0 -2.968** 0.003
Perceived behavioral control (self-efficacy)a
I have the required skills to help my patients quit smoking. 3.0 (2.0) 2.0 – 4.0 4.0 (1.0) 4.0 – 5.0 -13.083 <0.001
I do not feel I have effective methods to assist my patients with 
quitting.
3.0 (2.0) 2.0 – 4.0 2.0 (2.0) 1.0 – 3.0 -7.949** <0.001
My patients follow my advice about behavior change. 3.0 (1.0) 3.0 – 4.0 4.0 (2.0) 3.0 – 5.0 -11.256 <0.001
My patients who smoke want to quit smoking. 3.0 (1.0) 3.0 – 4.0 4.0 (2.0) 3.0 – 5.0 -6.931 <0.001
I know where to refer patients for help with smoking cessation. 4.0 (3.0) 4.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -10.388 <0.001
Intentionsa
Address tobacco use with all my patients as priority. 4.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -4.414 <0.001
Document tobacco use status in the patient’s medical record. 5.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -6.703 <0.001
Offer my support to all my patients making a quit attempt. 5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -7.022 <0.001
Provide brief smoking cessation counseling (3–5 minutes). 5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -5.586 <0.001
Give my patients written materials about quitting smoking. 5.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -4.719 <0.001
Discuss available quit-smoking medications with my patients who 
smoke.
4.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -9.726 <0.001
Prescribe a quit smoking medication for patients ready to quit. 4.0 (3.0) 2.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -8.345 <0.001
Schedule dedicated appointment to develop quit plans with my 
patients.
4.0 (2.0) 3.0 – 5.0 5.0 (1.0) 4.0 – 5.0 -7.327 <0.001
Be persistent in addressing tobacco use with my patients even if I 
am not effective the first time.
5.0 (1.0) 4.0 – 5.0 5.0 (0.0) 5.0 – 5.0 -5.911 <0.001
Importance of helping patients quit smokingb 10.0 (1.0) 9.0 – 10.0 10.0 (0.0) 10.0 - 10.0 -4.731 <0.001
a On a scale from 1 to 5 (strongly disagree to strongly agree). b On a scale from 1 to 10. *Based on negative ranks. **Based on positive ranks. ***IQR: interquartile range. Post 
period: missing data n=2.
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based tobacco treatment interventions. This is 
important as recent European population-based 
studies have found that many patients report that they 
did not receive any advice or support to quit during 
a healthcare visit1,12,13. 
Results from a recent systematic review highlighted 
that digital education was at least as effective as 
traditional or usual learning, resulting in similar or 
higher improvement in knowledge and satisfaction, 
and sometimes in the attitude of the healthcare 
professionals, following digital education compared 
with conventional learning4. This is an essential aspect 
as eLearning courses and in general digital education 
can increase educational opportunities14 by providing 
training and new skills to healthcare professionals 
who want to integrate tobacco-dependence treatment 
into their daily clinical practice15,16 and at the same 
time overcome the barrier of distance in healthcare 
professionals’ education14. 
Previous results, from our team, also showed 
that evidence-based training increases healthcare 
workforce self-efficacy, competence, knowledge and 
attitudes related to tobacco treatment7 and improves 
the rates at which evidence-based tobacco treatment 
is delivered to patients8,9. Additionally, pre-post 
studies evaluating the impact of the tobacco treatment 
guidelines and training for patients with multiple 
morbidities (CVD, diabetes and COPD) also showed 
significant increases in physicians’ knowledge and 
self-efficacy immediately following and at 6 months 
after exposure to training sessions10. Significant 
increases were also recorded in knowledge, self-
efficacy and rates at which doctors delivered evidence-
based tobacco treatment following exposure to a live 
educational intervention11. All the above support 
the findings of our study. However, a follow-up, 
preferably at 6 months, after the completion of the 
eLearning course, would be useful to evaluate the 
sustainability of our results and also the level of the 
implementation in the healthcare providers’ daily 
clinical practice. 
 Previous studies have identified a lack of 
knowledge and skills among healthcare professionals 
as a key barrier to the delivery of smoking cessation 
advice17. In addition, due to lack of knowledge, low 
motivation, perceived low self-efficacy and concerns 
about inadequate time and workload, many healthcare 
professionals do not provide effective cessation 
services17,18. However, implementation of tobacco 
dependence treatment for healthcare professionals 
has been shown to increase their cessation efforts 
significantly with their patients and quit attempts19,20, 
as well as improve trainees’ attitudes and perceived 
behavioral control in providing tobacco dependence 
services21. The importance of continuing medical 
education training programs to address this gap in 
knowledge and skills has also been acknowledged 
and can significantly impact healthcare professional 
competence, future clinical practice and patient 
outcomes if embedded into the healthcare system22-26. 
Based on all the aforementioned, time and distance 
saving and cost-effective training programs that 
provide new knowledge and skills are essential to 
ensure that healthcare professionals are confident to 
deliver smoking cessation interventions to all their 
patients who smoke.
Strengths and limitations
Previous research that has evaluated digital education 
for smoking cessation until now has mainly focused 
on patient interventions27,28. In contrast, our research 
has focused on training healthcare professionals. We 
present a novel approach by using a pre-post design 
to monitor the change at the participant level for a 
broad representation of the healthcare professionals 
from many European countries. 
However, as the eLearning course was accredited, 
there were some restrictions on the procedure of 
the completion of the course, as participants had 
to successfully complete each module’s test to 
receive accreditation. In addition, the profile of 
the participants and the voluntary nature of our 
course may mean that the participants were more 
motivated than the general population of healthcare 
professionals. On the other hand, for the same reasons, 
the course healthcare professionals may have over-
performed in their responses for changing attitude 
norms, perceived behavioral control and intentions 
in delivering tobacco treatment interventions with 
their patients who smoke. For these reasons, the 
generalizability of our findings requires further 
investigation.
CONCLUSIONS 
The ENSP eLearning intervention, built on evidence-
based tobacco treatment eLearning courses, was 
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associated with significant increases in healthcare 
professional’s knowledge, attitudes, normative beliefs, 
perceived behavioral control and intention to integrate 
tobacco treatment delivery into daily clinical practice. 
Future research should examine supplementary 
methods for supporting the broader dissemination 
of well-designed digital interventions and eLearning 
programs, and develop targeted strategies for all 
healthcare professionals.
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